S&P 500   3,342.72 (-0.26%)
DOW   27,595.61 (+0.59%)
QQQ   267.99 (-1.29%)
AAPL   442.09 (-0.53%)
MSFT   206.42 (-2.85%)
FB   260.77 (-2.86%)
GOOGL   1,482.99 (-1.03%)
AMZN   3,105.11 (-1.97%)
NVDA   435.53 (-2.78%)
CGC   18.00 (+8.24%)
BABA   246.33 (-2.29%)
TSLA   1,391.54 (-4.21%)
MU   48.38 (-0.76%)
GE   6.66 (+3.90%)
AMD   79.81 (-5.94%)
T   30.16 (+0.47%)
F   7.07 (+3.06%)
ACB   10.06 (-2.04%)
GILD   68.51 (-1.21%)
NFLX   480.98 (-2.78%)
DIS   129.02 (-0.71%)
BAC   26.76 (+2.49%)
BA   177.56 (+4.43%)
S&P 500   3,342.72 (-0.26%)
DOW   27,595.61 (+0.59%)
QQQ   267.99 (-1.29%)
AAPL   442.09 (-0.53%)
MSFT   206.42 (-2.85%)
FB   260.77 (-2.86%)
GOOGL   1,482.99 (-1.03%)
AMZN   3,105.11 (-1.97%)
NVDA   435.53 (-2.78%)
CGC   18.00 (+8.24%)
BABA   246.33 (-2.29%)
TSLA   1,391.54 (-4.21%)
MU   48.38 (-0.76%)
GE   6.66 (+3.90%)
AMD   79.81 (-5.94%)
T   30.16 (+0.47%)
F   7.07 (+3.06%)
ACB   10.06 (-2.04%)
GILD   68.51 (-1.21%)
NFLX   480.98 (-2.78%)
DIS   129.02 (-0.71%)
BAC   26.76 (+2.49%)
BA   177.56 (+4.43%)
S&P 500   3,342.72 (-0.26%)
DOW   27,595.61 (+0.59%)
QQQ   267.99 (-1.29%)
AAPL   442.09 (-0.53%)
MSFT   206.42 (-2.85%)
FB   260.77 (-2.86%)
GOOGL   1,482.99 (-1.03%)
AMZN   3,105.11 (-1.97%)
NVDA   435.53 (-2.78%)
CGC   18.00 (+8.24%)
BABA   246.33 (-2.29%)
TSLA   1,391.54 (-4.21%)
MU   48.38 (-0.76%)
GE   6.66 (+3.90%)
AMD   79.81 (-5.94%)
T   30.16 (+0.47%)
F   7.07 (+3.06%)
ACB   10.06 (-2.04%)
GILD   68.51 (-1.21%)
NFLX   480.98 (-2.78%)
DIS   129.02 (-0.71%)
BAC   26.76 (+2.49%)
BA   177.56 (+4.43%)
S&P 500   3,342.72 (-0.26%)
DOW   27,595.61 (+0.59%)
QQQ   267.99 (-1.29%)
AAPL   442.09 (-0.53%)
MSFT   206.42 (-2.85%)
FB   260.77 (-2.86%)
GOOGL   1,482.99 (-1.03%)
AMZN   3,105.11 (-1.97%)
NVDA   435.53 (-2.78%)
CGC   18.00 (+8.24%)
BABA   246.33 (-2.29%)
TSLA   1,391.54 (-4.21%)
MU   48.38 (-0.76%)
GE   6.66 (+3.90%)
AMD   79.81 (-5.94%)
T   30.16 (+0.47%)
F   7.07 (+3.06%)
ACB   10.06 (-2.04%)
GILD   68.51 (-1.21%)
NFLX   480.98 (-2.78%)
DIS   129.02 (-0.71%)
BAC   26.76 (+2.49%)
BA   177.56 (+4.43%)
Log in

NASDAQ:FENCFennec Pharmaceuticals Stock Price, Forecast & News

Add
Compare
Today's Range N/A
50-Day Range
$8.06
MA: $8.69
$9.39
52-Week Range N/A
Volume750,635 shs
Average Volume335,476 shs
Market Capitalization$228.46 million
P/E RatioN/A
Dividend YieldN/A
Beta0.25
Fennec Pharmaceuticals Inc., a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was founded in 1996 and is based in Research Triangle Park, North Carolina.
Read More
Fennec Pharmaceuticals logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.38 out of 5 stars


Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:FENC
CUSIPN/A
Phone919-636-4530

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$0.60 per share

Profitability

Net Income$-12,770,000.00

Miscellaneous

EmployeesN/A
Market Cap$228.46 million
Next Earnings Date11/10/2020 (Estimated)
OptionableOptionable
30 days | 90 days | 365 days | Advanced Chart

Receive FENC News and Ratings via Email

Sign-up to receive the latest news and ratings for FENC and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Fennec Pharmaceuticals (NASDAQ:FENC) Frequently Asked Questions

Do Wall Street analysts recommend investors buy shares of Fennec Pharmaceuticals?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Fennec Pharmaceuticals in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Fennec Pharmaceuticals
.

When is Fennec Pharmaceuticals' next earnings date?

Fennec Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, November 10th 2020.
View our earnings forecast for Fennec Pharmaceuticals
.

How were Fennec Pharmaceuticals' earnings last quarter?

Fennec Pharmaceuticals Inc (NASDAQ:FENC) announced its quarterly earnings data on Wednesday, August, 5th. The company reported ($0.21) earnings per share for the quarter, missing analysts' consensus estimates of ($0.18) by $0.03.
View Fennec Pharmaceuticals' earnings history
.

What price target have analysts set for FENC?

3 brokers have issued 12 month price targets for Fennec Pharmaceuticals' stock. Their forecasts range from $15.00 to $18.00. On average, they anticipate Fennec Pharmaceuticals' stock price to reach $17.00 in the next year.
View analysts' price targets for Fennec Pharmaceuticals
.

Has Fennec Pharmaceuticals been receiving favorable news coverage?

News stories about FENC stock have been trending very positive on Monday, according to InfoTrie Sentiment Analysis. The research firm identifies positive and negative media coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Fennec Pharmaceuticals earned a media sentiment score of 3.2 on InfoTrie's scale. They also gave media stories about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the company's share price in the near future.
View the latest news about Fennec Pharmaceuticals
.

Are investors shorting Fennec Pharmaceuticals?

Fennec Pharmaceuticals saw a decrease in short interest in July. As of July 31st, there was short interest totaling 1,220,000 shares, a decrease of 10.3% from the July 15th total of 1,360,000 shares. Based on an average daily trading volume, of 256,600 shares, the days-to-cover ratio is presently 4.8 days. Currently, 5.7% of the company's stock are sold short.
View Fennec Pharmaceuticals' Short Interest
.

Who are some of Fennec Pharmaceuticals' key competitors?

What other stocks do shareholders of Fennec Pharmaceuticals own?

Who are Fennec Pharmaceuticals' key executives?

Fennec Pharmaceuticals' management team includes the following people:
  • Mr. Rostislav Raykov, Pres, CEO & Director (Age 42)
  • Mr. Robert C. Andrade, Chief Financial Officer (Age 43)
  • Mr. Mark Gowland, Controller
  • Mr. Lei Fang, Pres of Pharstat Inc
  • Ms. Anne McKay, Regulatory Consultant (Age 64)

What is Fennec Pharmaceuticals' stock symbol?

Fennec Pharmaceuticals trades on the NASDAQ under the ticker symbol "FENC."

Who are Fennec Pharmaceuticals' major shareholders?

Fennec Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional investors include Cadence Capital Management LLC (0.61%), Hartford Financial Management Inc. (0.20%), Wedbush Securities Inc. (0.13%), New York State Common Retirement Fund (0.08%), Strs Ohio (0.06%) and SG Americas Securities LLC (0.05%).
View institutional ownership trends for Fennec Pharmaceuticals
.

Which major investors are buying Fennec Pharmaceuticals stock?

FENC stock was acquired by a variety of institutional investors in the last quarter, including New York State Common Retirement Fund, Strs Ohio, SG Americas Securities LLC, Wedbush Securities Inc., Hartford Financial Management Inc., UBS Group AG, and Cadence Capital Management LLC.
View insider buying and selling activity for Fennec Pharmaceuticals
.

How do I buy shares of Fennec Pharmaceuticals?

Shares of FENC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

How big of a company is Fennec Pharmaceuticals?

Fennec Pharmaceuticals has a market capitalization of $0.00. The company earns $-12,770,000.00 in net income (profit) each year or ($0.64) on an earnings per share basis.

What is Fennec Pharmaceuticals' official website?

The official website for Fennec Pharmaceuticals is www.fennecpharma.com.

How can I contact Fennec Pharmaceuticals?

Fennec Pharmaceuticals' mailing address is PO BOX 13628 68 TW ALEXANDER DRIVE, DURHAM NC, 27709. The company can be reached via phone at 919-636-4530.

This page was last updated on 8/10/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.